Anti-aldosterones save lives in STEMI heart attack patients: ALBATROSS, REMINDER

August 28, 2017, European Society of Cardiology

Certain heart attack patients who have ST-segment elevation myocardial infarction (STEMI) are significantly more likely to survive if they are treated immediately with anti-aldosterone-type drugs in addition to standard therapy, according to new research presented at ESC Congress today.

Formerly considered diuretics, mineralocorticoid receptor antagonists (MRAs) "are still underused in routine clinical practice, but our data may hopefully contribute to expanded use of these life-saving and low-cost drugs," said study investigator Prof Farzin Beygui, MD, PhD, from the ACTION Study Group, and Centre Hospitalier Universitaire de Caen, France.

MRAs such as spironolactone and eplerenone can offset the damaging effect of high aldosterone levels - which rise immediately after a heart attack - augmenting the benefits of optimal standard therapy including reperfusion therapy, beta-blockers, dual antiplatelet therapy, statins and ACE inhibitors, explained Prof Beygui.

The study pooled data from the previously published ALBATROSS and REMINDER trials, both of which were underpowered individually to fully assess the impact of MRA regimens.

Although ALBATROSS (Aldosterone Lethal effects Blockade in Acute myocardial infarction Treated with or without Reperfusion to improve Outcome and Survival at Six months follow-up) failed to demonstrate the benefit of a spironolactone-based MRA regimen compared to standard therapy alone, it was tested in a mixed group of STEMI and non-STEMI patients. "There was a suggested potential significant mortality reduction in the STEMI subgroup, that was worth investigating further" he explained.

The REMINDER (Randomized, Placebo-Controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction) trial only included STEMI patients, and showed that eplerenone added to standard therapy within the first 24 hours, was more effective compared to standard therapy alone in reducing a clinico-biological endpoint.

For the current analysis, Prof Beygui and his team pooled results from the full REMINDER study group and the STEMI subgroup of ALBATROSS.

In total, across the two trials, 2241 patients were randomly assigned to the addition of an MRA to standard therapy (1118 patients) or standard alone (1123 controls).

After a median follow-up of 190 days, there were significantly fewer deaths in the MRA-treated patients compared to controls (0.4 % vs 1.6%, stratified odds ratio 0.22; 95% CI 0.07-0.65, p=0.006).

"The evidence from our analysis is not as strong as from a specifically designed randomised trial, however the reduction of mortality in STEMI supports the use of MRAs in this indication," concluded Prof Beygui. "These findings highlight the need for more studies that are adequately sized and specifically designed to confirm the potentially major clinical benefit associated with these low-cost treatments."

Explore further: Antimineralocorticoids offer no benefit in heart attack patients without heart failure

Related Stories

Antimineralocorticoids offer no benefit in heart attack patients without heart failure

August 30, 2015
Heart attack patients without heart failure derive no benefit from the addition of mineralocortoid receptor antagonists (MRA), to standard therapy, results of the ALBATROSS study show.

Mineralocorticoid receptor antagonists no benefit post MI

April 19, 2016
(HealthDay)—For patients with post-myocardial infarction (MI) heart failure, mineralocorticoid receptor antagonists (MRAs) do not improve outcome, according to a study published in the April 26 issue of the Journal of the ...

Gender gap in death from heart attack reduces particularly in younger women

August 27, 2017
The gender gap in death from heart attack has reduced over the past two decades particularly in younger women, according to research presented today at ESC Congress. The study in over 50 000 patients found that overall in-hospital ...

Oxygen therapy does not improve survival in patients with heart attack symptoms

August 28, 2017
Oxygen therapy does not improve survival in patients with heart attack symptoms, according to late-breaking research presented today in a Hot Line LBCT Session at ESC Congress and published in the NEJM.

Eplerenone reduces primary endpoint in acute myocardial infarction patients

April 29, 2014
A drug known to reduce mortality rate in patients with heart failure has now been found significantly effective when administered early in patients following an acute (ST elevated) myocardial infarction. This effect,say the ...

ESC Guidelines on ST-segment elevation myocardial infarction published today

August 26, 2017
European Society of Cardiology (ESC) Guidelines on the management of acute myocardial infarction in patients with ST-segment elevation are published online today in European Heart Journal, and on the ESC website.

Recommended for you

Heart researchers develop a new, promising imaging technique for cardiac arrhythmias

February 22, 2018
Every five minutes in Germany alone, a person dies of sudden cardiac arrest or fibrillation, the most common cause of death worldwide. This is partly due to the fact that doctors still do not fully understand exactly what ...

Scientists use color-coded tags to discover how heart cells develop

February 22, 2018
UCLA researchers used fluorescent colored proteins to trace how cardiomyocytes—cells in heart muscle that enable it to pump blood—are produced in mouse embryos. The findings could eventually lead to methods for regenerating ...

'Beetroot pill' could help save patients from kidney failure after heart X-ray

February 22, 2018
Beetroot may reduce the risk of kidney failure in patients having a heart x-ray, according to research led by Queen Mary University of London.

Women once considered low risk for heart disease show evidence of previous heart attack scars

February 20, 2018
Women who complain about chest pain often are reassured by their doctors that there is no reason to worry because their angiograms show that the women don't have blockages in the major heart arteries, a primary cause of heart ...

Resolvin D-1 limits kidney damage after heart attacks

February 20, 2018
A heart attack triggers an acute inflammatory response at the damaged portion of the heart's left ventricle. If this acute inflammation lingers, it can lead to stretching of the ventricle and heart failure. The inflammation ...

Can your cardiac device be hacked?

February 20, 2018
Medical devices, including cardiovascular implantable electronic devices could be at risk for hacking. In a paper publishing online today in the Journal of the American College of Cardiology, the American College of Cardiology's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.